ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma

Sponsor
Lymphoma Study Association
Study ID
NCT00144807
Phase
PHASE2
Status
Completed

Conditions

  • Diffuse Large Cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 59 Years
Healthy Volunteers
Not accepted

Interventions

  • rituximab — DRUG
  • doxorubicin — DRUG
  • cyclophosphamide — DRUG
  • autologous stem cell transplantation — PROCEDURE

Study Details

This study is a multicentric trial evaluating the efficacy of R-ACVBP in patients aged 18 to 59 years with high risk diffuse large B-cell lymphoma

Key Dates

Start date
Dec 31, 2003
Status verified
Sep 2015
Primary completion
Sep 30, 2008
Completion
Apr 30, 2012

Study Design

Enrollment
128 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: R-AC
    rituximab + doxorubicin + cyclophosphamide + autologous stem cell transplantation

Primary Outcome Measure

Complete remission rate (CR + CRu) [ Time Frame: 12 weeks ]

Related Studies